These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 21524678

  • 1. Comparative protective effects of HI-6 and MMB-4 against organophosphorous nerve agent poisoning.
    Lundy PM, Hamilton MG, Sawyer TW, Mikler J.
    Toxicology; 2011 Jul 29; 285(3):90-6. PubMed ID: 21524678
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in soman, cyclosarin and tabun-poisoned rats.
    Kassa J, Jun D, Karasova J, Bajgar J, Kuca K.
    Chem Biol Interact; 2008 Sep 25; 175(1-3):425-7. PubMed ID: 18547554
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Estimation of oxime efficacy in nerve agent poisoning: a kinetic approach.
    Worek F, Szinicz L, Thiermann H.
    Chem Biol Interact; 2005 Dec 15; 157-158():349-52. PubMed ID: 16266695
    [Abstract] [Full Text] [Related]

  • 7. Pyridinium oximes: rationale for their selection as causal antidotes against organophosphate poisonings and current solutions for auto-injectors.
    Stojiljković MP, Jokanović M.
    Arh Hig Rada Toksikol; 2006 Dec 15; 57(4):435-43. PubMed ID: 17265683
    [Abstract] [Full Text] [Related]

  • 8. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning.
    Lundy PM, Raveh L, Amitai G.
    Toxicol Rev; 2006 Dec 15; 25(4):231-43. PubMed ID: 17288495
    [Abstract] [Full Text] [Related]

  • 9. New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning.
    Berend S, Vrdoljak AL, Radić B, Kuca K.
    Chem Biol Interact; 2008 Sep 25; 175(1-3):413-6. PubMed ID: 18547553
    [Abstract] [Full Text] [Related]

  • 10. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis.
    Worek F, Eyer P, Aurbek N, Szinicz L, Thiermann H.
    Toxicol Appl Pharmacol; 2007 Mar 25; 219(2-3):226-34. PubMed ID: 17112559
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the efficacy of a bispyridinium oxime--1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods.
    Kuca K, Cabal J, Kassa J.
    Pharmazie; 2004 Oct 25; 59(10):795-8. PubMed ID: 15544060
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of HI 6 treatment after percutaneous VR exposure by use of a kinetic-based dynamic computer model.
    Aurbek N, Thiermann H, Szinicz L, Worek F.
    Toxicology; 2007 Apr 20; 233(1-3):173-9. PubMed ID: 16904808
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Restoration of nerve agent inhibited muscle force production in human intercostal muscle strips with HI 6.
    Seeger T, Niessen KV, Langer P, Gerhardus J, Worek F, Friess H, Bumm R, Mihaljevic AL, Thiermann H.
    Toxicol Lett; 2011 Sep 25; 206(1):72-6. PubMed ID: 21803135
    [Abstract] [Full Text] [Related]

  • 15. Comparison of reactivating and therapeutic efficacy of two salts of the oxime HI-6 against tabun, soman and cyclosarin in rats.
    Kassa J, Jun D, Kuca K, Bajgar J.
    Basic Clin Pharmacol Toxicol; 2007 Nov 25; 101(5):328-32. PubMed ID: 17910616
    [Abstract] [Full Text] [Related]

  • 16. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents.
    Kassa J.
    J Toxicol Clin Toxicol; 2002 Nov 25; 40(6):803-16. PubMed ID: 12475193
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the potency of newly developed oximes (K074, K075) and commonly used oximes (obidoxime, HI-6) to counteract tabun-induced neurotoxicity in rats.
    Kassa J, Karasova J.
    Toxicology; 2007 Jan 05; 229(1-2):136-44. PubMed ID: 17141392
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the neuroprotective efficacy of newly developed oximes (K206, K269) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats.
    Kassa J, Karasova JZ, Bajgar J, Tesarova S, Kuca K, Musilek K.
    Basic Clin Pharmacol Toxicol; 2009 Mar 05; 104(3):228-35. PubMed ID: 19143747
    [Abstract] [Full Text] [Related]

  • 19. An evaluation of reactivating and therapeutic efficacy of newly developed oximes (K206, K269) and commonly used oximes (obidoxime, HI-6) in cyclosarin-poisoned rats and mice.
    Kassa J, Karasova J, Musilek K, Kuca K, Bajgar J.
    Clin Toxicol (Phila); 2009 Jan 05; 47(1):72-6. PubMed ID: 18686075
    [Abstract] [Full Text] [Related]

  • 20. In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs.
    Shih TM, Skovira JW, O'Donnell JC, McDonough JH.
    Chem Biol Interact; 2010 Sep 06; 187(1-3):207-14. PubMed ID: 20223229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.